Published in Blood on January 08, 2008
miR-125b-2 is a potential oncomiR on human chromosome 21 in megakaryoblastic leukemia. Genes Dev (2010) 2.05
Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome. Blood (2009) 1.84
Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971. Blood (2011) 1.81
Altered hematopoiesis in trisomy 21 as revealed through in vitro differentiation of isogenic human pluripotent cells. Proc Natl Acad Sci U S A (2012) 1.62
GATA1-mutant clones are frequent and often unsuspected in babies with Down syndrome: identification of a population at risk of leukemia. Blood (2013) 1.60
Perturbation of fetal liver hematopoietic stem and progenitor cell development by trisomy 21. Proc Natl Acad Sci U S A (2012) 1.46
Developmental stage-specific interplay of GATA1 and IGF signaling in fetal megakaryopoiesis and leukemogenesis. Genes Dev (2010) 1.42
The landscape of somatic mutations in Down syndrome-related myeloid disorders. Nat Genet (2013) 1.31
Down syndrome and malignancies: a unique clinical relationship: a paper from the 2008 william beaumont hospital symposium on molecular pathology. J Mol Diagn (2009) 1.29
MicroRNA-486-5p is an erythroid oncomiR of the myeloid leukemias of Down syndrome. Blood (2014) 1.23
Malignancy in children with trisomy 21. Oncologist (2009) 1.12
The prenatal origins of cancer. Nat Rev Cancer (2014) 1.09
Constitutional aneuploidy and cancer predisposition. Hum Mol Genet (2009) 1.05
Histone deacetylase inhibitors induce apoptosis in myeloid leukemia by suppressing autophagy. Leukemia (2013) 1.00
Myeloid leukemia in Down syndrome. Crit Rev Oncog (2011) 0.99
Hematological disorders and leukemia in children with Down syndrome. Eur J Pediatr (2011) 0.95
Transient myeloproliferative disorder in a newborn with down syndrome treated with rasburicase for the risk of development of tumor lysis syndrome: A case report. J Med Case Rep (2011) 0.85
Development of acute megakaryoblastic leukemia in Down syndrome is associated with sequential epigenetic changes. Blood (2013) 0.84
Developmental differences in IFN signaling affect GATA1s-induced megakaryocyte hyperproliferation. J Clin Invest (2013) 0.81
Prognosis and management of acute myeloid leukemia in patients with Down syndrome. Expert Rev Hematol (2014) 0.81
GATA1s induces hyperproliferation of eosinophil precursors in Down syndrome transient leukemia. Leukemia (2013) 0.81
Acute megakaryoblastic leukemia with acquired trisomy 21 and GATA1 mutations in phenotypically normal children. Eur J Pediatr (2014) 0.80
Stem and progenitor cell dysfunction in human trisomies. EMBO Rep (2014) 0.79
Normal karyotype is a poor prognostic factor in myeloid leukemia of Down syndrome: a retrospective, international study. Haematologica (2013) 0.78
A unique role of GATA1s in Down syndrome acute megakaryocytic leukemia biology and therapy. PLoS One (2011) 0.76
The impact of trisomy 21 on foetal haematopoiesis. Blood Cells Mol Dis (2013) 0.76
Myeloid Proliferations Associated with Down Syndrome. J Hematop (2014) 0.75
Transient Abnormal Myelopoiesis and AML in Down Syndrome: an Update. Curr Hematol Malig Rep (2016) 0.75
Clinical characteristics and laboratory analyses of acute myeloid leukemia with t(16;21)(p11;q22). Oncol Lett (2015) 0.75
Transient abnormal myelopoiesis/acute megakaryoblastic leukemia diagnosed in the placenta of a stillborn Down syndrome fetus with targeted next-generation sequencing. Leukemia (2014) 0.75
Transient abnormal myelopoesis in an infant with Down syndrome. Libyan J Med (2010) 0.75
Down syndrome and leukemia: insights into leukemogenesis and translational targets. Transl Pediatr (2015) 0.75
Sometimes it is better to wait: First Italian case of a newborn with transient abnormal myelopoiesis and a favorable prognosis. Oncol Lett (2016) 0.75
Familial Myelodysplastic/Acute Leukemia Syndromes-Myeloid Neoplasms with Germline Predisposition. Front Oncol (2017) 0.75
Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep (1966) 48.83
Multiple sequence alignment with the Clustal series of programs. Nucleic Acids Res (2003) 38.75
Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet (2002) 5.55
An inherited mutation leading to production of only the short isoform of GATA-1 is associated with impaired erythropoiesis. Nat Genet (2006) 2.74
A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481. Blood (2006) 2.58
Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1. Nat Genet (2005) 2.44
Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling. Proc Natl Acad Sci U S A (2006) 2.08
Simultaneous occurrence of mongolism and leukemia; report of a nationwide survey. AMA J Dis Child (1957) 2.07
Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498. Blood (1992) 1.97
Myelodysplasia and acute myelogenous leukemia in Down's syndrome. A report of 40 children of the AML-BFM Study Group. Leukemia (1996) 1.96
Transient leukaemia--a benign form of leukaemia in newborn infants with trisomy 21. Br J Haematol (2003) 1.95
Incidence and treatment of potentially lethal diseases in transient leukemia of Down syndrome: Pediatric Oncology Group Study. J Pediatr Hematol Oncol (2002) 1.78
Transient abnormal myelopoiesis of infancy associated with trisomy 21. Am J Pediatr Hematol Oncol (1993) 1.74
AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity. Leukemia (2005) 1.51
Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia. Blood (2005) 1.51
Sequencing multimegabase-template DNA with BigDye terminator chemistry. Genome Res (1998) 1.47
Pattern of malignant disorders in individuals with Down's syndrome. Lancet Oncol (2001) 1.46
Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis. Blood (2003) 1.37
Fetal and neonatal leukemia. J Pediatr Hematol Oncol (2003) 1.34
Incidence and clinical implications of GATA1 mutations in newborns with Down syndrome. Blood (2007) 1.23
Immunophenotype of Down syndrome acute myeloid leukemia and transient myeloproliferative disease differs significantly from other diseases with morphologically identical or similar blasts. Klin Padiatr (2005) 1.15
Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93. J Clin Oncol (2001) 1.15
Acute megakaryoblastic leukemia in children and adolescents, excluding Down's syndrome: improved outcome with intensified induction treatment. Leukemia (2005) 1.14
Leukemia and/or myeloproliferative syndrome in neonates with Down syndrome. Semin Perinatol (1997) 1.04
Novel RUNX1 isoforms determine the fate of acute myeloid leukemia cells by controlling CD56 expression. Blood (2007) 0.97
Life-threatening complications of transient abnormal myelopoiesis in neonates with Down syndrome. Eur J Pediatr (2004) 0.90
Down's syndrome: the effects of prenatal diagnosis and demographic factors in a region of the eastern part of Germany. Eur J Epidemiol (2000) 0.88
Janus kinase mutations in the development of acute megakaryoblastic leukemia in children with and without Down's syndrome. Leukemia (2007) 0.87
Ascites and pleural effusion secondary to extramedullary hematopoiesis. Am J Med Sci (1999) 0.83
Clinical manifestations of hematologic and oncologic disorders in patients with Down syndrome. Am J Med Genet C Semin Med Genet (2006) 0.82
Concomitant aberrant overexpression of RUNX1 and NCAM in regenerating bone marrow of myeloid leukemia of Down's syndrome. Haematologica (2006) 0.80
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature (2012) 10.99
Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell (2012) 6.71
Clinical implications of FLT3 mutations in pediatric AML. Blood (2006) 2.72
Outcomes after induction failure in childhood acute lymphoblastic leukemia. N Engl J Med (2012) 2.60
Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood (2009) 2.57
Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk. Nat Genet (2010) 2.47
Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood (2012) 2.39
Molecular allelokaryotyping of pediatric acute lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide genomic microarray. Blood (2007) 2.31
Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood (2011) 2.18
Cardiac involvement in Churg-Strauss syndrome: impact of endomyocarditis. Medicine (Baltimore) (2009) 2.14
Diagnostic cerebrospinal fluid examination in children with acute lymphoblastic leukemia: significance of low leukocyte counts with blasts or traumatic lumbar puncture. J Clin Oncol (2003) 2.12
Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling. Proc Natl Acad Sci U S A (2006) 2.08
High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. Blood (2011) 2.08
miR-125b-2 is a potential oncomiR on human chromosome 21 in megakaryoblastic leukemia. Genes Dev (2010) 2.05
Osteonecrosis: a treatment related toxicity in childhood acute lymphoblastic leukemia (ALL)--experiences from trial ALL-BFM 95. Pediatr Blood Cancer (2005) 2.02
Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group. J Clin Oncol (2013) 1.97
Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia. Blood (2009) 1.94
A review on allogeneic stem cell transplantation for newly diagnosed pediatric acute myeloid leukemia. Blood (2010) 1.91
Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma. Acta Neuropathol (2011) 1.90
TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma. J Clin Oncol (2010) 1.83
Mutations in the von Hippel-Lindau (VHL) tumor suppressor gene and VHL-haplotype analysis in patients with presumable congenital erythrocytosis. Haematologica (2005) 1.83
Distinct mutations in STXBP2 are associated with variable clinical presentations in patients with familial hemophagocytic lymphohistiocytosis type 5 (FHL5). Blood (2012) 1.82
Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98. J Clin Oncol (2006) 1.82
Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia. J Clin Oncol (2010) 1.79
Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. J Clin Oncol (2004) 1.76
Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. JAMA (2005) 1.74
Evaluation of gene expression signatures predictive of cytogenetic and molecular subtypes of pediatric acute myeloid leukemia. Haematologica (2010) 1.71
Longitudinal evaluation of early and late anthracycline cardiotoxicity in children with AML. Pediatr Blood Cancer (2007) 1.69
Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover. Proc Natl Acad Sci U S A (2013) 1.66
FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance. Blood (2003) 1.65
NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern. Blood (2011) 1.64
Intensive chemotherapy for childhood acute lymphoblastic leukemia: results of the randomized intercontinental trial ALL IC-BFM 2002. J Clin Oncol (2013) 1.62
High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicine. Blood (2010) 1.62
GLUT1 mutations are a cause of paroxysmal exertion-induced dyskinesias and induce hemolytic anemia by a cation leak. J Clin Invest (2008) 1.60
Do centrally pre-prepared solutions achieve more reliable drug concentrations than solutions prepared on the ward? Intensive Care Med (2011) 1.57
miRNAs can increase the efficiency of ex vivo platelet generation. Ann Hematol (2012) 1.57
Activating mutations in human acute megakaryoblastic leukemia. Blood (2008) 1.56
Pharmacology of all-trans-retinoic acid in children with acute promyelocytic leukemia. Med Pediatr Oncol (2003) 1.52
Leukemia-associated NF1 inactivation in patients with pediatric T-ALL and AML lacking evidence for neurofibromatosis. Blood (2008) 1.51
IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol. Haematologica (2012) 1.50
Topical topic: accidental cisplatin overdose in a child: reversal of acute renal failure with sodium thiosulfate. Med Pediatr Oncol (2002) 1.48
Molecular profiling of pediatric mature B-cell lymphoma treated in population-based prospective clinical trials. Blood (2008) 1.47
Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98. J Clin Oncol (2010) 1.47
Variation at 10p12.2 and 10p14 influences risk of childhood B-cell acute lymphoblastic leukemia and phenotype. Blood (2013) 1.45
CNS irradiation in pediatric acute myleoid leukemia: equal results by 12 or 18 Gy in studies AML-BFM98 and 2004. Pediatr Blood Cancer (2011) 1.44
Treatment results of childhood acute lymphoblastic leukemia in Austria--a report of 20 years' experience. Wien Klin Wochenschr (2002) 1.43
Developmental stage-specific interplay of GATA1 and IGF signaling in fetal megakaryopoiesis and leukemogenesis. Genes Dev (2010) 1.42
Impact of different post-remission strategies on quality of life in patients with acute myeloid leukemia. Haematologica (2008) 1.41
The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. Br J Haematol (2005) 1.37
High expression levels of x-linked inhibitor of apoptosis protein and survivin correlate with poor overall survival in childhood de novo acute myeloid leukemia. Clin Cancer Res (2004) 1.36
International variations in infection supportive care practices for paediatric patients with acute myeloid leukaemia. Br J Haematol (2009) 1.35
Cloning of genes involved in chromosomal translocations by high-resolution single nucleotide polymorphism genomic microarray. Proc Natl Acad Sci U S A (2008) 1.34
Treatment options in childhood pontine gliomas. J Neurooncol (2006) 1.26
Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: results of an international study. Blood (2011) 1.25
Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group. J Clin Oncol (2006) 1.25
Impact of cranial radiotherapy on central nervous system prophylaxis in children and adolescents with central nervous system-negative stage III or IV lymphoblastic lymphoma. J Clin Oncol (2006) 1.24
Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004. Blood (2013) 1.23
Prognostic factors in childhood anaplastic large cell lymphoma: results of a large European intergroup study. Blood (2007) 1.23